DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Healthcare
Author Program NEWCreate Narrative
VNRX logo

VolitionRx Limited Stock Price

NYSEAM:VNRX Community·US$4.0m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 21 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

VNRX Share Price Performance

US$0.26
-13.34 (-98.09%)
​
US$2.00
Fair Value
US$0.26
-13.34 (-98.09%)
87.0% undervalued intrinsic discount
US$2.00
Fair Value
Price US$0.26
AnalystLowTarget US$2.00
AnalystConsensusTarget US$13.62
AnalystHighTarget US$24.00
Thu, 3 Sep 26
Fair ValueUS$2.00
Share Pricen/a

VNRX Community Narratives

AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$2 87.0% undervalued intrinsic discount

Early Cancer Detection Headwinds Will Persist Yet Long-Term Liquid Biopsy Potential Remains

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$13.62 98.1% undervalued intrinsic discount

Blood Diagnostics Partnerships And NETs Platform Will Drive Long Term Upside Potential

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$24 98.9% undervalued intrinsic discount

Epigenetic Diagnostics And NETs Platform Will Reshape Long Term Prospects In Cancer And Autoimmune Care

0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
VNRX logo
VolitionRx
98.1% undervalued intrinsic discount
Updated

Blood Diagnostics Partnerships And NETs Platform Will Drive Long Term Upside Potential

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 17 Sep
Read Narrative
VNRX logo
VolitionRx
87.0% undervalued intrinsic discount

Early Cancer Detection Headwinds Will Persist Yet Long-Term Liquid Biopsy Potential Remains

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 3 Sep
Read Narrative
VNRX logo
VolitionRx
98.9% undervalued intrinsic discount

Epigenetic Diagnostics And NETs Platform Will Reshape Long Term Prospects In Cancer And Autoimmune Care

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 24 Jul
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
VNRX logo

VNRX: Sepsis And Lung Cancer Data Will Drive Repricing Potential

Fair Value: US$13.62 98.1% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
VNRX logo

VNRX: Turnaround Will Rely On Advancing Liquid Biopsy And Sepsis Testing

Fair Value: US$2 87.0% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
VNRX logo

VNRX: New Diagnostics Progress And Reduced Share Authorization Will Drive Repricing

Fair Value: US$24 98.9% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Medium-low risk with high growth potential.

6 Risks
2 Rewards
View Full Analysis

VolitionRx Limited Key Details

US$2.5m

Revenue

US$0

Cost of Revenue

US$2.5m

Gross Profit

US$28.6m

Other Expenses

-US$26.1m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-1.84
100.00%
-1,061.82%
-31.9%
View Full Analysis

About VNRX

Founded
n/a
Employees
57
CEO
Cameron Reynolds
WebsiteView website
volition.com

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient’s cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.

Recent VNRX News & Updates

User avatar
Narrative Update • Sep 17

VNRX: Sepsis And Lung Cancer Data Will Drive Repricing Potential

Analysts have revised their price target on VolitionRx to $13.62 from $16.97, citing updated assumptions for discount rates, revenue growth, profit margins, and future P/E expectations. What's in the News for VolitionRx VolitionRx reported that its lateral flow finger prick prototype for Nu.Q NETs showed strong correlation with the existing CE marked automated Nu.Q NETs lab assay in critically ill sepsis patients, which could open use at the bedside, in emergency rooms, and in regions with limited lab infrastructure.

Recent updates

No updates

VolitionRx Limited Competitors

XCRT logo

Xcelerate

Symbol: OTCPK:XCRT
Market cap: US$7.8m
LUCY logo

Lucyd

Symbol: NasdaqCM:LUCY
Market cap: US$7.7m
ACON logo

Aclarion

Symbol: NasdaqCM:ACON
Market cap: US$7.6m
BICX logo

BioCorRx

Symbol: OTCPK:BICX
Market cap: US$7.5m
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide